NUTX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Nutex Health Inc (NUTX) is not a good buy at the moment for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's recent financial performance shows significant declines in revenue, net income, and gross margin. Additionally, the pre-market price drop of -26.54% and lack of strong technical or trading signals suggest caution. While the company demonstrated strong growth in fiscal year 2025, the recent quarterly results indicate a sharp downturn, making it unsuitable for long-term investment at this time.
The MACD is above 0 but positively contracting, indicating weakening momentum. The RSI is neutral at 41.653, and moving averages are converging, showing no clear trend. The stock is currently trading below key support levels, with a pre-market price of 77.3826, significantly below S2 at 95.308.
Nutex Health achieved 82% revenue growth in fiscal year 2025, driven by strong performance in its hospital division. The company reported a profit of $70.79 million for the past year, marking a significant improvement from the previous year.
Q4 2025 revenue declined by 41.1% YoY, net income dropped by 80.79% YoY, and gross margin fell by 44.67%. The pre-market price is down -26.54%, indicating negative sentiment. Analysts may view the sharp quarterly downturn as a red flag.
In Q4 2025, revenue dropped to $151.7 million (-41.12% YoY), net income fell to $11.83 million (-80.79% YoY), EPS declined to 1.74 (-80.45% YoY), and gross margin decreased to 30.42% (-44.67% YoY). Despite strong fiscal year 2025 growth, the latest quarter shows significant financial deterioration.
No specific analyst rating or price target changes were provided. Wall Street sentiment appears cautious given the recent financial performance and pre-market price drop.
